Skip to main content
Albert David Ltd. logo

Albert David Ltd. — Investor Relations & Filings

Ticker · ALBERTDAVD ISIN · INE155C01010 LEI · 3358007IQAE63N68CT31 BSE.NS Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2026-05-13 Earnings Release
Country IN India
Listing BSE.NS ALBERTDAVD

About Albert David Ltd.

https://www.albertdavidindia.com

Albert David Ltd. specializes in the manufacturing and marketing of pharmaceutical formulations, infusions, and herbal preparations. The company’s product portfolio encompasses a wide range of therapeutic segments, including anti-infectives, gastrointestinal agents, and ophthalmic solutions. A significant area of expertise lies in the production of large and small volume parenterals and specialized placenta extract-based treatments used for tissue regeneration and wound healing. The organization maintains advanced production facilities and focuses on research and development to support its diverse clinical offerings. Its operations serve a broad spectrum of healthcare needs across various global markets, emphasizing quality control and technical precision in its manufacturing processes.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Earnings Release Classification · 85% confidence The document is a formal filing to the BSE and NSE notifying the publication in newspapers of the extract of audited financial results for the fourth quarter and full year ended March 31, 2026. It contains key financial highlights (the summary of income, profit/loss, EPS, etc.) rather than full annual statements. This aligns with an initial announcement of quarterly/periodic financial results (an Earnings Release), not a full interim report or annual report. Therefore, it should be classified as an Earnings Release (ER). FY 2026
2026-05-13 English
Newspaper publication of Extract of Audited Financial Result for the fourth quarter and year ended 31st March, 2026
Earnings Release Classification · 85% confidence The document is a letter from the company secretary to the BSE and NSE submitting the “Newspaper publication of Extract of Audited Financial Results for the Fourth Quarter and Year ended March 31, 2026.” It includes key financial highlights (total income, net profit, EPS) in a tabular extract intended for regulatory publication under SEBI LODR Regulation 47. This is not a full Annual Report (10-K) or detailed Interim Report (IR) but an initial announcement of periodical results (summary/extract) published in newspapers. It therefore matches the definition of an Earnings Release (ER). FY 2026
2026-05-13 English
Regulation 30(5) of SEBI ( LODR), 2015 KMP''S authorised to determine materiality under Regulation 30(5) of SEBI (LODR), 2015
Regulatory Filings Classification · 88% confidence The document is a formal SEBI Listing Regulations disclosure titled “Outcome of the Board Meeting” filed with the BSE and NSE. It summarizes board decisions taken on May 12, 2026, including (i) the appointment of a new CEO, (ii) approval of audited financial results for Q4 and FY ended March 31, 2026, accompanied by the Independent Auditor’s Report, (iii) dividend recommendation, (iv) AGM date, record date, (v) reappointment of internal and cost auditors, and (vi) updated KMP contact details. This is not the full Annual Report (10-K) or Interim Report (IR), nor just a proxy statement or dividend notice. Its primary purpose is regulatory compliance—furnishing disclosures under SEBI LODR Regulations. Therefore it best fits the “Regulatory Filings” (RNS) category as a general compliance announcement.
2026-05-12 English
General Updates
Regulatory Filings Classification · 84% confidence The document is a formal ‘Outcome of the Board Meeting’ notice submitted to stock exchanges under SEBI Listing Regulations. It covers multiple board resolutions—appointment of a CEO, approval of audited quarterly and annual results, dividend recommendation, AGM schedule, record date, re‐appointment of auditors, etc. It is not the full annual report or standalone audit report, nor is it a proxy statement or dividend notice in isolation. This is a general regulatory announcement/disclosure to the exchanges. Under our taxonomy, such catch‐all compliance disclosures fall into Regulatory Filings (RNS).
2026-05-12 English
Book closure date
Regulatory Filings Classification · 78% confidence The document is a composite disclosure under SEBI’s Listing Regulations (Reg. 30 & 33) titled “Outcome of the Board Meeting,” sent to BSE & NSE. It covers a range of items (appointment of a CEO, audited financial results attachment, dividend recommendation, AGM scheduling, auditor re-appointments, KMP contact details, etc.). Although the audited results are attached, this is not a standalone annual or interim report filing but rather a regulatory announcement of multiple board decisions. It does not fit neatly into the specific “Interim/Quarterly Report” or “Board/Management Information” buckets alone, so it falls into the fallback “Regulatory Filings” (RNS) category.
2026-05-12 English
Record date fixed on 30th July 2026 for the purpose of final dividend and determining members eligible to vote for 87th AGM.
Regulatory Filings Classification · 82% confidence The document is a stock exchange submission under SEBI Listing Regulations disclosing the outcome of the Board meeting, including CEO appointment, audited results (with audit report annexed), dividend recommendation, AGM scheduling, auditors’ appointments, and KMP contact updates. It is a general regulatory announcement covering multiple items rather than the full financial report itself or a standalone board change notice only. Therefore, it best fits the “Regulatory Filings (RNS)” category as a miscellaneous compliance disclosure.
2026-05-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.